Please assess the completion status of the following clinical trial:

Trial Title: Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA~* Planned treatment with radical radiotherapy with or without concurrent cisplatin chemotherapy.~* Age ≥ 18 years.~Exclusion Criteria:~* Any anticancer treatment for their cervical cancer.~* Eastern Cooperative Oncology Group (ECOG) performance status \> 2~* Other cervical cancer tumor histologies (e.g. small cell, serous)~* Contraindications to 18FDG PET-CT~* Inability to lie supine for 18FDG PET-CT~* Contraindication to radiotherapy (e.g. severe Crohn's disease)~* History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 5 years.~* Known pregnancy or lactating

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperpolarized Pyruvate (13C) Injection (Type: ACTIVE_COMPARATOR): Participants will be injected with the study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43 ml/kg and will have their cervix imaged using MRI.
- 18F-FDG (Type: ACTIVE_COMPARATOR): Participants will be injected with the study drug 18F-FDG at a dose of 5 MBq/kg to a a maximum of 500 MBq (megabecquerel) and will have their cervix imaged using PET-CT imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).